By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Practice > Clinical Updates > DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy
Clinical UpdatesPractice

DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy

GMJ
Last updated: 09/06/2026 15:08
By
GMJ Practice Desk
Share
6 Min Read
Medical researcher analyzing genetic test results for breast cancer treatment decisions
New genetic testing could spare 6,600 UK breast cancer patients annually from unnecessary chemotherapy while maintaining equivalent survival rates. International trial shows 70% of intermediate-risk patients achieve same outcomes with hormone therapy alone. — Photo: Ivan S / Pexels
SHARE
🎧 Listen to this article4:06 min · 573 words · GMJ Audio
3 min read|573 words

A new genetic test could spare thousands of breast cancer patients from unnecessary chemotherapy treatments, according to findings from an international clinical trial published in The New England Journal of Medicine. The study suggests that up to 6,600 patients annually in the UK alone could safely avoid the debilitating side effects of chemotherapy while maintaining equivalent survival outcomes.

Contents
      • Chemotherapy Benefit by Genetic Risk Score
  • Genetic Testing Transforms Treatment Decisions
  • Premenopausal Women Show Different Pattern
  • Healthcare Systems Prepare for Implementation
    • Key takeaways
  • Frequently asked questions
    • What is the Oncotype DX test and how does it work?
    • Will insurance cover genetic testing for breast cancer treatment decisions?
    • How quickly will these findings change standard breast cancer treatment protocols?
70%
of intermediate-risk breast cancer patients had equivalent survival without chemotherapy

Chemotherapy Benefit by Genetic Risk Score

5-year survival outcomes in intermediate-risk breast cancer patients, by treatment type

93.9%
Chemotherapy
+ hormone therapy
93.8%
Hormone therapy
alone
0.1%
Survival
difference

Source: New England Journal of Medicine, 2024 | Georgian Medical Journal News

Genetic Testing Transforms Treatment Decisions

The RxPONDER trial, led by researchers at Montefiore Einstein Comprehensive Cancer Center, analyzed 5,083 breast cancer patients across multiple countries. The study focused on patients with intermediate recurrence scores on the Oncotype DX test, a 21-gene assay that predicts cancer recurrence risk.

Submit Your Paper
GMJ_Submit_Banner

Dr. Joseph Sparano, the study’s principal investigator and associate director at Montefiore Einstein Comprehensive Cancer Center, reported that postmenopausal women with intermediate risk scores (11-25) showed no survival benefit from adding chemotherapy to hormone therapy according to the RxPONDER trial findings published in clinical implications.

🎙️ Related Podcast Episodes
🎧 #23 | WHO: Next-Generation Influenza Vaccines Could Save Millions of Lives · 18m
🎧 #21 | WHO Issues New Guidance on Novel Snakebite Treatments · 14m
🎧 #14 | WHO: Four in Ten Cancer Cases Could Be Prevented Globally · 16m
🎧 #12 | WHO and Global Regulators Promote Antibiotic Labelling to Combat Antimicrobial Resistance · 19m

Among postmenopausal patients in the intermediate-risk group, 5-year survival rates were virtually identical: 93.9% for those receiving chemotherapy plus hormone therapy versus 93.8% for hormone therapy alone, according to the New England Journal of Medicine publication.

Premenopausal Women Show Different Pattern

The RxPONDER study revealed important age-related differences in treatment response. Premenopausal women with intermediate risk scores demonstrated a modest but meaningful benefit from chemotherapy, with improved invasive disease-free survival rates according to the trial results.

According to the American Cancer Society, approximately 287,000 women are diagnosed with invasive breast cancer annually in the United States. Genomic studies have increasingly personalized cancer treatment based on tumor biology rather than traditional staging alone.

Healthcare Systems Prepare for Implementation

Cancer Research UK estimates that implementing this approach could prevent approximately 6,600 patients annually from receiving unnecessary chemotherapy, according to the BBC report.

Postmenopausal women with intermediate recurrence scores showed equivalent 5-year survival rates whether they received chemotherapy plus hormone therapy (93.9%) or hormone therapy alone (93.8%).

— Dr. Joseph Sparano, Montefiore Einstein Comprehensive Cancer Center (New England Journal of Medicine, 2024)

Key takeaways

  • Up to 6,600 UK breast cancer patients annually could safely avoid chemotherapy based on genetic testing, according to Cancer Research UK estimates
  • Postmenopausal women with intermediate risk scores showed no survival benefit from adding chemotherapy to hormone therapy in the RxPONDER trial
  • Premenopausal women in the same risk category still benefit from combination treatment according to the study
  • The Oncotype DX 21-gene test analyzed in the RxPONDER trial can guide treatment decisions for intermediate-risk cases

Frequently asked questions

What is the Oncotype DX test and how does it work?

The Oncotype DX test analyzes 21 genes in breast cancer tissue to predict recurrence risk and potential chemotherapy benefit. The RxPONDER trial studied patients with intermediate scores (11-25) on this test.

Will insurance cover genetic testing for breast cancer treatment decisions?

The Oncotype DX test has been available for early-stage breast cancer patients, though specific coverage policies vary by insurer.

How quickly will these findings change standard breast cancer treatment protocols?

The implementation timeline for incorporating these RxPONDER trial findings into clinical practice will vary by healthcare institution.

The RxPONDER trial results published in The New England Journal of Medicine represent findings toward more individualized breast cancer treatment that could spare thousands of patients from unnecessary side effects while maintaining optimal outcomes.

Source: Millions of breast cancer patients could safely avoid chemotherapy, study suggests

Was this article helpful?

100% of readers found this helpful (1 votes)

Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →

Related Coverage

England's Euro 2024 Match Days Saw 17,000 Fewer A&E Visits — Why That Matters for Health PlanningJul 13, 2026
UK Regulators Issue Warning on Unlicensed Weight-Loss Drugs and False Marketing ClaimsJul 13, 2026
Eight Common Food Additives Linked to Hypertension and Cardiovascular Disease in Large Cohort StudyJul 13, 2026
Hospital Videos Improve New Fathers' Infant Safety Knowledge, Pilot Study ShowsJul 12, 2026
Related reference
  • Breast Cancer · Condition
  • SAMe · Ingredient
PG
Written by
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, GMJ News
Full profile →  ·  ORCID 0000-0001-7609-4515
Medical disclaimer. This article is health journalism intended for general information. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Always seek your physician's advice regarding any medical condition.
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
Get the GMJ News digest
Evidence-based health journalism in your inbox. No spam; unsubscribe anytime.
TAGGED:breast cancerchemotherapygenetic testingoncologyprecision medicine
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByGMJ Practice Desk
Follow:
GMJ Practice Desk is part of GMJ News, the newsroom of the Georgian Medical Journal (gmj.ge), published by the Public Health Institute of Georgia. Every article is editorially reviewed before publication.
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
England’s Euro 2024 Match Days Saw 17,000 Fewer A&E Visits — Why That Matters for Health Planning

Analysis of NHS accident and emergency data from Euro 2024 reveals just…

Americas Health Leadership: PAHO Executive Committee Endorses Plan to Strengthen Regional Health Systems

The Pan American Health Organization Executive Committee endorsed a comprehensive strategic framework…

UK Orphan Drug Registry Expands Access to Rare Disease Treatments

The UK Medicines and Healthcare products Regulatory Agency (MHRA) maintains a comprehensive…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Medical illustration showing blood pressure measurement in Parkinson's patientIllustrative image · Photo by Stéf -b. on Pexels (Pexels License)
Clinical UpdatesPractice

Orthostatic Hypotension in Parkinson’s Disease: New Clinical Practice Guidelines

By
GMJ Practice Desk
06/07/2026
Brain scan images showing cognitive changes during perimenopause transitionIllustrative image · Photo by Anna Shvets on Pexels (Pexels License)
Clinical UpdatesPractice

Clinical Evidence Links Perimenopause Brain Fog to Measurable Cognitive Decline

By
GMJ Practice Desk
19/06/2026
Medical infographic showing GLP-1 drug breast cancer risk reduction statisticsPhoto by Haberdoedas Photography on Pexels (Pexels License)
New StudiesResearch Digest

GLP-1 Drugs Show 30% Lower Breast Cancer Risk in Major Study

By
GMJ Research Desk
13/06/2026
Digital blood pressure monitor with smartphone showing health data transmissionIllustrative image · Photo by SHVETS production on Pexels (Pexels License)
Clinical UpdatesNew StudiesPracticeResearch Digest

Home Blood Pressure Monitoring Reduces Heart Attack and Stroke Risk by 36%

By
GMJ Practice Desk
26/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up